Back to results
US 2023/0399320 A1Published application
Novel capsid assembly inhibitor
AssigneePelemed Co., Ltd.
InventorsYong Chul Kim, Sung Gyoo Park, Jiwon Seo, Woo Chan Kim, Jae Hoon Jung, Yuri Cho, Yoon Jun Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.
Claims16
A compound represented by Formula 1 or a pharmaceutically acceptable salt thereof:
- wherein,
- m is 0, 1 or 2;
- n is an integer from 0 to 4;
- Y is C(H) or N;
- R1 is C1-4 alkyl;
- R2 is hydrogen, halogen, amino, —NH—(CH2)p—NHCO—R5, or
- C6-10 aryl, C6-10 arylamino, 3-10 membered heterocyclyl, or 3-10 membered heterocyclylamino each unsubstituted or substituted by R6;
- R5 is tert-butoxy, C6-10 aryl or 5-10 membered heteroaryl;
- R6 is amino unsubstituted or substituted by tert-butoxycarbonyl, or
- tert-butoxy, C6-10 aryl, or 5-10 membered heteroaryl linked directly or through —CO—,
- p is an integer from 1 to 4;
- R3 is hydrogen, 3-10 membered heterocyclyl, cyano, C1-4 alkyl, C1-4 haloalkyl, or 1 to 3 halogens;
- and
- R4 is hydrogen, or C6-10 aryl-C1-4 alkyl;
- wherein said aryl, heteroaryl and heterocyclyl are unsubstituted or substituted by one or more selected from halogen, C1-4 alkyl, C1-4 alkoxy, or amino.
12 more elements
A method for preparing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, the method comprising:
- Step 1:
- preparing a compound represented by Formula 4-1 by reacting a compound represented by Formula 2-1 with an amine derivative represented by Formula 3;
- and
- optionally, when R4 is not hydrogen, Step 2:
- preparing a compound represented by Formula 6 by reacting a compound represented by Formula 4-1 with a halide derivative represented by Formula 5;
- wherein,
- X1 to X3 are each independently halogen;
- X is X1 or
- m is 0, 1, or 2;
- n is an integer from 0 to 4;
- Y is C(H) or N;
- R1 is C1-4 alkyl;
- R2 is hydrogen, halogen, amino, —NH—(CH2)p—NHCO—R5, or
- C6-10 aryl, C6-10 arylamino, 3-10 membered heterocyclyl, or 3-10 membered heterocyclylamino each unsubstituted or substituted by R6;
- R5 is tert-butoxy, C6-10 aryl or 5-10 membered heteroaryl;
- R6 is tert-butoxy, C6-10 aryl or 5-10 membered heteroaryl linked directly or through —CO—;
- p is an integer from 1 to 4;
- R3 is hydrogen, 3-10 membered heterocyclyl, cyano, C1-4 alkyl, C1-4 haloalkyl, or 1 to 3 halogens;
- and
- R4 is hydrogen, or C6-10 aryl-C1-4 alkyl;
- wherein said aryl, heteroaryl and heterocyclyl are unsubstituted or substituted by one or more selected from halogen, C1-4 alkyl, C1-4 alkoxy, or amino.
18 more elements
A method for preparing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, the method comprising:
- Step 1:
- preparing a compound represented by Formula 4 by reacting a compound represented by Formula 2-2 with an amine derivative represented by Formula 3;
- and
- Step 2:
- preparing a compound a compound represented by Formula 34 by reacting a compound represented by Formula 4-2 with a Boc-protected diamine derivative represented by Formula 9;
- wherein,
- X1 and X2 are each independently halogen;
- m is 2;
- n is an integer from 0 to 4;
- R1 is C1-4 alkyl;
- R2 is
- R6 is —CO-tert-butoxy;
- q is 0, 1 or 2;
- r is 1 or 2;
- R3 is hydrogen, 3-10 membered heterocyclyl, cyano, C1-4 alkyl, C1-4 haloalkyl or 1 to 3 halogens;
- and
- R4 is hydrogen;
- wherein said heterocyclyl is unsubstituted or substituted by one or more selected from halogen or amino.
15 more elements
Dependencies are inferred from the claim text.